Bromodomain-containing protein 4: The epigenetic origin of pulmonary arterial hypertension

Circulation Research

Volumn 117, Issue 6, 2015, Pages 525-535

  Meloche, Jolyane ^a   Potus, François ^a   Vaillancourt, Mylène ^a   Bourgeois, Alice ^a   Johnson, Ian ^a   Deschamps, Laure ^a   Chabot, Sophie ^a   Ruffenach, Grégoire ^a   Henry, Sarah ^a   Breuils Bonnet, Sandra ^a   Tremblay, Ève ^a   Nadeau, Valérie ^a   Lambert, Caroline ^a   Paradis, Renée ^a   Provencher, Steeve ^a   Bonnet, Sébastien ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

epigenomics; human BRD4 protein; microRNA; pulmonary hypertension; vascular remodeling

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; BROMODOMAIN CONTAINING PROTEIN 4; MICRORNA; MICRORNA 204; PROTEIN; PROTEIN BCL 2; PROTEIN P21; SMALL INTERFERING RNA; SURVIVIN; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; BRD4 PROTEIN, HUMAN; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; EPIGENETICS; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; HYPOXIA-INDUCED PULMONARY HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY ARTERY SMOOTH MUSCLE CELL; RAT; UPREGULATION; AGED; ANIMAL; BIOSYNTHESIS; CELL CULTURE; GENETIC EPIGENESIS; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PULMONARY ARTERY; PULMONARY HYPERTENSION;

ADULT; AGED; ANIMALS; CELLS, CULTURED; EPIGENESIS, GENETIC; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PULMONARY ARTERY; RATS; TRANSCRIPTION FACTORS;

EID: 84940503934     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.307004     Document Type: Article

References (51)

1. Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F, Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol 2011 8 443 455. doi: 10.1038/nrcardio.2011.87
2. Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S, An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007 30 104 109. doi: 10.1183/09031936.00092306
3. Humbert M, Sitbon O, Chaouat A, Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006 173 1023 1030. doi: 10.1164/rccm.200510-1668OC
4. Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M, A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 2007 30 1103 1110. doi: 10.1183/09031936.00042107
5. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, Giles S, Feldkircher K, Miller DP, McGoon MD, Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010 137 376 387. doi: 10.1378/chest.09-1140
6. Escribano-Subias P, Blanco I, López-Meseguer M, Lopez-Guarch CJ, Roman A, Morales P, Castillo-Palma MJ, Segovia J, Gómez-Sanchez MA, Barberà JA, REHAP investigators Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J 2012 40 596 603. doi: 10.1183/09031936.00101211
7. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD, An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012 142 448 456. doi: 10.1378/chest.11-1460
8. Meloche J, Pflieger A, Vaillancourt M, Paulin R, Potus F, Zervopoulos S, Graydon C, Courboulin A, Breuils-Bonnet S, Tremblay E, Couture C, Michelakis ED, Provencher S, Bonnet S, Role for DNA damage signaling in pulmonary arterial hypertension. Circulation 2014 129 786 797. doi: 10.1161/CIRCULATIONAHA.113.006167
9. Bonnet S, Rochefort G, Sutendra G, Archer SL, Haromy A, Webster L, Hashimoto K, Bonnet SN, Michelakis ED, The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci U S A 2007 104 11418 11423. doi: 10.1073/pnas.0610467104
10. Courboulin A, Paulin R, Giguère NJ, Saksouk N, Perreault T, Meloche J, Paquet ER, Biardel S, Provencher S, Côté J, Simard MJ, Bonnet S, Role for miR-204 in human pulmonary arterial hypertension. J Exp Med 2011 208 535 548. doi: 10.1084/jem.20101812
11. Lamoureux F, Baud'huin M, Rodriguez Calleja L, Jacques C, Berreur M, Rédini F, Lecanda F, Bradner JE, Heymann D, Ory B, Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle. Nat Commun 2014 5 3511. doi: 10.1038/ncomms4511
12. Wyce A, Ganji G, Smitheman KN, BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. PLoS One 2013 8 e72967. doi: 10.1371/journal.pone.0072967
13. Baratta MG, Schinzel AC, Zwang Y, An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc Natl Acad Sci U S A 2015 112 232 237. doi: 10.1073/pnas.1422165112
14. Tolani B, Gopalakrishnan R, Punj V, Matta H, Chaudhary PM, Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors. Oncogene 2014 33 2928 2937. doi: 10.1038/onc.2013.242
15. Gallagher SJ, Mijatov B, Gunatilake D, Tiffen JC, Gowrishankar K, Jin L, Pupo GM, Cullinane C, Prinjha RK, Smithers N, McArthur GA, Rizos H, Hersey P, The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells. J Invest Dermatol 2014 134 2795 2805. doi: 10.1038/jid.2014.243
16. Belkina AC, Denis GV, BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer 2012 12 465 477. doi: 10.1038/nrc3256
17. Segura MF, Fontanals-Cirera B, Gaziel-Sovran A, Guijarro MV, Hanniford D, Zhang G, González-Gomez P, Morante M, Jubierre L, Zhang W, Darvishian F, Ohlmeyer M, Osman I, Zhou MM, Hernando E, BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. Cancer Res 2013 73 6264 6276. doi: 10.1158/0008-5472.CAN-13-0122-T
18. Rahman S, Sowa ME, Ottinger M, Smith JA, Shi Y, Harper JW, Howley PM, The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. Mol Cell Biol 2011 31 2641 2652. doi: 10.1128/MCB.01341-10
19. Kanno T, Kanno Y, LeRoy G, Campos E, Sun HW, Brooks SR, Vahedi G, Heightman TD, Garcia BA, Reinberg D, Siebenlist U, O'Shea JJ, Ozato K, BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones. Nat Struct Mol Biol 2014 21 1047 1057. doi: 10.1038/nsmb.2912
20. Devaiah BN, Lewis BA, Cherman N, Hewitt MC, Albrecht BK, Robey PG, Ozato K, Sims RJ III, Singer DS, BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proc Natl Acad Sci U S A 2012 109 6927 6932. doi: 10.1073/pnas.1120422109
21. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB, Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 2009 104 236 2444, 28p following 244. doi: 10.1161/CIRCRESAHA.108.182014
22. Yu L, Quinn DA, Garg HG, Hales CA, Cyclin-dependent kinase inhibitor p27Kip1, but not p21WAF1/Cip1, is required for inhibition of hypoxia-induced pulmonary hypertension and remodeling by heparin in mice. Circ Res 2005 97 937 945. doi: 10.1161/01.RES.0000188211.83193.1a
23. Kanno S, Wu YJ, Lee PC, Billiar TR, Ho C, Angiotensin-converting enzyme inhibitor preserves p21 and endothelial nitric oxide synthase expression in monocrotaline-induced pulmonary arterial hypertension in rats. Circulation 2001 104 945 950
24. Filippakopoulos P, Qi J, Picaud S, Selective inhibition of BET bromodomains. Nature 2010 468 1067 1073. doi: 10.1038/nature09504
25. Hill BG, Benavides GA, Lancaster JR Jr, Ballinger S, Dell'Italia L, Jianhua Z, Darley-Usmar VM, Integration of cellular bioenergetics with mitochondrial quality control and autophagy. Biol Chem 2012 393 1485 1512. doi: 10.1515/hsz-2012-0198
26. Larsen S, Nielsen J, Hansen CN, Nielsen LB, Wibrand F, Stride N, Schroder HD, Boushel R, Helge JW, Dela F, Hey-Mogensen M, Biomarkers of mitochondrial content in skeletal muscle of healthy young human subjects. J Physiol 2012 590 3349 3360. doi: 10.1113/jphysiol.2012.230185
27. Meloche J, Le Guen M, Potus F, Vinck J, Ranchoux B, Johnson I, Antigny F, Tremblay E, Breuils-Bonnet S, Perros F, Provencher S, Bonnet S, MiR-223 Reverses experimental pulmonary arterial hypertension [published online ahead of print June 17, 2015]. Am J Physiol Cell Physiol. doi: 10.1152/ajpcell.00149.2015. http://ajpcell.physiology.org/content/early/2015/06/15/ajpcell.00149.2015
28. Paulin R, Courboulin A, Meloche J, Mainguy V, Dumas de la Roque E, Saksouk N, Côté J, Provencher S, Sussman MA, Bonnet S, Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension. Circulation 2011 123 1205 1215. doi: 10.1161/CIRCULATIONAHA.110.963314
29. Paulin R, Michelakis ED, The metabolic theory of pulmonary arterial hypertension. Circ Res 2014 115 148 164. doi: 10.1161/CIRCRESAHA.115.301130
30. McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G, Bonnet S, Puttagunta L, Michelakis ED, Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 2005 115 1479 1491. doi: 10.1172/JCI23203
31. Paulin R, Meloche J, Jacob MH, Bisserier M, Courboulin A, Bonnet S, Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol 2011 301 H1798 H1809. doi: 10.1152/ajpheart.00654.2011
32. Ray S, Zhao Y, Jamaluddin M, Edeh CB, Lee C, Brasier AR, Inducible STAT3 NH2 terminal mono-ubiquitination promotes BRD4 complex formation to regulate apoptosis. Cell Signal 2014 26 1445 1455. doi: 10.1016/j.cellsig.2014.03.007
33. Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, Peth K, Portier BP, Rodriguez M, Devaraj SG, Zhan M, Sheng J, Iyer SP, Bradner JE, Bhalla KN, Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol Cancer Ther 2014 13 1142 1154. doi: 10.1158/1535-7163.MCT-13-0770
34. Yu J, Wilson J, Taylor L, Polgar P, DNA microarray and signal transduction analysis in pulmonary artery smooth muscle cells from heritable and idiopathic pulmonary arterial hypertension subjects. J Cell Biochem 2015 116 386 397. doi: 10.1002/jcb.24987
35. Meloche J, Courchesne A, Barrier M, Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology. J Am Heart Assoc 2013 2 e005157. doi: 10.1161/JAHA.112.005157
36. Rabinovitch M, PPARgamma and the pathobiology of pulmonary arterial hypertension. Adv Exp Med Biol 2010 661 447 458. doi: 10.1007/978-1-60761-500-2-29
37. Li M, Li Z, Sun X, Yang L, Fang P, Liu Y, Li W, Xu J, Lu J, Xie M, Zhang D, Heme oxygenase-1/p21WAF1 mediates peroxisome proliferator-activated receptor-gamma signaling inhibition of proliferation of rat pulmonary artery smooth muscle cells. FEBS J 2010 277 1543 1550. doi: 10.1111/j.1742-4658.2010.07581.x
38. Zhang D, Wang G, Han D, Zhang Y, Xu J, Lu J, Li S, Xie X, Liu L, Dong L, Li M, Activation of PPAR-γ ameliorates pulmonary arterial hypertension via inducing heme oxygenase-1 and p21(WAF1): an in vivo study in rats. Life Sci 2014 98 39 43. doi: 10.1016/j.lfs.2013.12.208
39. Wang F, Liu H, Blanton WP, Belkina A, Lebrasseur NK, Denis GV, Brd2 disruption in mice causes severe obesity without Type 2 diabetes. Biochem J 2010 425 71 83. doi: 10.1042/BJ20090928
40. Belkina AC, Nikolajczyk BS, Denis GV, BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J Immunol 2013 190 3670 3678. doi: 10.4049/jimmunol.1202838
41. Khan YM, Kirkham P, Barnes PJ, Adcock IM, Brd4 is essential for IL-1β-induced inflammation in human airway epithelial cells. PLoS One 2014 9 e95051. doi: 10.1371/journal.pone.0095051
42. Klein K, Kabala PA, Grabiec AM, Gay RE, Kolling C, Lin LL, Gay S, Tak PP, Prinjha RK, Ospelt C, Reedquist KA, The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts [published online ahead of print December 2, 2014]. Ann Rheum Dis. doi: 10.1136/annrheumdis-2014-205809. http://ard.bmj.com/content/early/2014/12/02/annrheumdis-2014-205809.abstract
43. Zou Z, Huang B, Wu X, Zhang H, Qi J, Bradner J, Nair S, Chen LF, Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA. Oncogene 2014 33 2395 2404. doi: 10.1038/onc.2013.179
44. Brown JD, Lin CY, Duan Q, NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis. Mol Cell 2014 56 219 231. doi: 10.1016/j.molcel.2014.08.024
45. Cohen-Kaminsky S, Hautefort A, Price L, Humbert M, Perros F, Inflammation in pulmonary hypertension: what we know and what we could logically and safely target first. Drug Discov Today 2014 19 1251 1256. doi: 10.1016/j.drudis.2014.04.007
46. Hautefort A, Girerd B, Montani D, Cohen-Kaminsky S, Price L, Lambrecht BN, Humbert M, Perros F, T-helper 17 cell polarization in pulmonary arterial hypertension. Chest 2015 147 1610 1620. doi: 10.1378/chest.14-1678
47. Mele DA, Salmeron A, Ghosh S, Huang HR, Bryant BM, Lora JM, BET bromodomain inhibition suppresses TH17-mediated pathology. J Exp Med 2013 210 2181 2190. doi: 10.1084/jem.20130376
48. Tang X, Peng R, Phillips JE, Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and in vivo models of lung fibrosis. Am J Pathol 2013 183 470 479. doi: 10.1016/j.ajpath.2013.04.020
49. Spiltoir JI, Stratton MS, Cavasin MA, Demos-Davies K, Reid BG, Qi J, Bradner JE, McKinsey TA, BET acetyl-lysine binding proteins control pathological cardiac hypertrophy. J Mol Cell Cardiol 2013 63 175 179. doi: 10.1016/j.yjmcc.2013.07.017
50. Paulin R, Sutendra G, Gurtu V, Dromparis P, Haromy A, Provencher S, Bonnet S, Michelakis ED, A miR-208-Mef2 axis drives the decompensation of right ventricular function in pulmonary hypertension. Circ Res 2015 116 56 69. doi: 10.1161/CIRCRESAHA.115.303910
51. Vonk Noordegraaf A, Galiè N, The role of the right ventricle in pulmonary arterial hypertension. Eur Respir Rev 2011 20 243 253. doi: 10.1183/09059180.00006511